<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="drug-table.xslt"?><drug name = "mitoXANTRONE inj VIAL">
<dose><value>12</value>
<value>10</value>
<value>10 - 14</value>
<value>8</value>
</dose>
<route><value>IV</value>
</route>
<strength><value>2 mg/mL</value>
</strength>
<frequency><value>ONCE</value>
<value>DAILY</value>
</frequency>
<instruction><value>Administer dose diluted in 50 mL 0.9% sodium chloride over 15 to 30 minutes.</value>
<value>for 5 days. Administer dose diluted in 50 mL 0.9% sodium chloride over 15 to 30 minutes.</value>
</instruction>
<volume><value>10 mL</value>
</volume>
<units><value>mg/m2</value>
</units>
<Population><value>ADULT</value>
<value>PEDIATRICS</value>
</Population>
<IndicationPRN></IndicationPRN>
<AdditionalNotes><value>Metastatic Breast Cancer. Recommend 50% dose reduction in patients with Bilirubin levels greater than 50 umol/L. MAXIMUM cumulative dose: 140 mg/m2 for patients with no prior RT or anthracyclines or normal cardiac function; 120 mg/m2 in patients with previous anthracycline, RT or cyclophosphamide use; 100 mg/m2 in patients with previous maximum dose anthracyclines, if cardiac assessment is acceptable.</value>
<value>Metastatic Breast Cancer, Relapsed Lymphoma. Recommend 50% dose reduction in patients with Bilirubin levels greater than 50 umol/L. MAXIMUM cumulative dose: 140 mg/m2 for patients with no prior RT or anthracyclines or normal cardiac function; 120 mg/m2 in patients with previous anthracycline, RT or cyclophosphamide use; 100 mg/m2 in patients with previous maximum dose anthracyclines, if cardiac assessment is acceptable.</value>
</AdditionalNotes>
<BackgroundInformation><value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=3424</value>
</BackgroundInformation>
<PRNInformation></PRNInformation>
<AHSFormularyStatus><value>Formulary.</value>
</AHSFormularyStatus>
<AHFSName><value>Antineoplastic Agents</value>
</AHFSName>
<HighAlert><value>YES</value>
</HighAlert>
</drug>